Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 3/20 | 0.36 |
| ▸ | ACACA | Q13085 | 3/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1076139 | 1.00 | SLC2A1 (0.42) | SLC2A1KCNH2CKS1BSKP1SKP2 | |
| SCHEMBL1267140 | 0.88 | KCNH2 (0.43) | SLC2A1KCNH2CKS1BSKP1SKP2 | |
| SCHEMBL1083619 | 0.88 | KCNH2 (0.43) | SLC2A1KCNH2CKS1BSKP1SKP2 | |
| SCHEMBL13315179 | 0.85 | KCNH2 (0.45) | SLC2A1KCNH2 | |
| SCHEMBL3149200 | 0.85 | ACACB (0.38) | KCNH2CKS1BSKP1SKP2ACACB | |
| SCHEMBL3154917 | 0.85 | ACACB (0.38) | KCNH2CKS1BSKP1SKP2ACACB | |
| SCHEMBL1722764 | 0.83 | KCNH2 (0.45) | KCNH2 | |
| SCHEMBL3552170 | 0.83 | KCNH2 (0.42) | SLC2A1KCNH2 | |
| SCHEMBL3552167 | 0.83 | KCNH2 (0.42) | SLC2A1KCNH2 | |
| SCHEMBL3546417 | 0.81 | KCNH2 (0.50) | SLC2A1KCNH2CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012961-B2 | Tricyclic antibiotics | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-09-06 | — | — | US | disclosed |
| US-20110039836-A1 | TRICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-17 | — | — | US | disclosed |
| EP-2276766-A1 | TRICYCLIC ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009128019-A1 | TRICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039836-A1 | TRICYCLIC ANTIBIOTICS | OPRM1, UBE2D3, METTL3 | SLC2A1 4373/4885KCNH2 924/4885CKS1B 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.